FDA accepts license application from ALK
The US FDA has agreed to review a license application for ALK’s immunotherapy tablet against house dust mite allergy. It brings the allergy drug maker one step closer to fulfilling its ambition of becoming a global player.
BY LOUISE WENDT JENSEN
ALK has been waiting for it for some time, and this morning the allergy drug group said in a stock market release that the US FDA has now accepted the biologics License Application (BLA) for its tablet-based vaccine against house dust mite allergy, submitted by its American partner Merck/MSD in February.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
ALK chief was weighed and found wanting
For abonnenter
.JPG)
ALK Chairman: We are targeting a European candidate
For abonnenter
ALK races against the clock on price approval
For abonnenter
